ACY-738

CAT: 0804-HY-19327-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-19327-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ACY-738 is a potent, selective and orally-bioavailable HDAC6 inhibitor, with an IC50 of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC50s of 94, 128, and 218 nM.
CAS Number
[1375465-91-0]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ACY-738.html
Purity
99.92
Solubility
DMSO : ≥ 32 mg/mL
Smiles
O=C(NO)C(C=N1)=CN=C1NC2(CC2)C3=CC=CC=C3
Molecular Formula
C14H14N4O2
Molecular Weight
270.29
Precautions
H302, H315, H319, H335
References & Citations
[1]Jochems J, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014 Jan;39 (2) :389-400.|[2]Regna NL, et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan;162:58-73.|[3]Mithraprabhu S, et al. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol. 2013 Aug;162 (4) :559-62.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC2; HDAC3; HDAC6

Popular Products